Association Between Neutrophil Percentage-to-Albumin Ratio and All-Cause Mortality and Cardiovascular Events in Patients with Diabetic Foot Ulcers: A Retrospective Cohort Study Authors: Maolin Tian, Lulu Liu, Yukun Tao, Jinzheng Hou, Guangxin Zhou, Li Xiao, Huijuan Zhu, Di Zhu, Da Zhang Published: 2026 ABSTRACT AbstractBackgroundPatients with diabetes-related foot ulcers (DFU) face a significantly elevated risk of cardiovascular events and mortality. The neutrophil percentage-to-albumin ratio (NPAR), as a composite inflammatory-nutritional biomarker, has not been thoroughly evaluated for its association with all-cause mortality, cardiovascular mortality, and major adverse cardiovascular events (MACE) in the DFU population.ObjectiveTo investigate the association between baseline NPAR levels and all-cause mortality, cardiovascular mortality, as well as MACE in patients with DFU.MethodsThis study enrolled 1175 patients diagnosed with DFU. Based on baseline NPAR quartiles, participants were categorized into four groups: Q1, Q2, Q3, and Q4. Multivariable Cox proportional hazards regression models were employed to calculate hazard ratios (HR) and corresponding 95% confidence intervals (CI). The associations between NPAR and the endpoint events were evaluated using subgroup analyses, Kaplan-Meier curves, and restricted cubic spline models, while the mediating role of eGFR was also examined.ResultsDuring a median follow-up of 3.6 years, a total of 360 all-cause deaths (30.64%), 236 cardiovascular deaths (20.09%), and 323 MACE (27.49%) were recorded. Multivariable-adjusted Cox proportional hazards regression analysis revealed that a per-unit increment in NPAR was associated with a 5% higher hazard of all-cause mortality and MACE, and a 6% higher hazard of cardiovascular mortality. Compared with the Q1 group, the Q4 group of NPAR demonstrated significantly higher risks of all-cause mortality (HR = 1.85), cardiovascular mortality (HR = 1.06), and MACE (HR = 1.05), with all p-values < 0.001. A piecewise regression model revealed that the saturation thresholds for these associations were identified at NPAR values of 20.2, 19.9, and 23.3, respectively. The mediating effects of eGFR accounted for 11.7%, 7.3%, and 8.7% of the total effects on all-cause mortality, cardiovascular mortality, and MACE, respectively.ConclusionElevated NPAR levels significantly increase the risk of all-cause mortality, cardiovascular mortality, and MACE in patients with DFU.Keywords: diabetic foot ulcer, neutrophil percentage-to-albumin ratio, (NPAR), all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, (MACE) Introduction Diabetes Mellitus (DM), particularly Type 2 Diabetes Mellitus (T2DM), represents a major global public health challenge, with its prevalence continuing to rise worldwide.1 Diabetes-related Foot Ulcer (DFU), one of the most common and serious complications of DM, substantially impairs patients’quality of life and imposes a substantial economic healthcare burden.2 While local wound management has advanced significantly, these strategies focus only on the wound site, without addressing the patient’s overall survival or cardiovascular prognosis.3,4 More critically, DFU patients face a markedly elevated risk of mortality. DFU is associated with a considerably higher all-cause mortality rate than diabetes without DFU, corresponding to a pooled relative risk of 2.45 (95% CI: 1.85–2.85).5 DFU is also a significant factor contributing to cardiovascular mortality.6 Evidence indicates that patients with DM face a markedly elevated risk of Major adverse cardiovascular events (MACE), with a 1.5-fold increase compared to non-diabetic individuals (adjusted OR 1.54, 95% CI 1.39–1.72), and DFU patients exhibit a significantly higher risk of experiencing such events.7 Consequently, there is an imperative need to identify more sensitive, integrative, and readily accessible prognostic biomarkers to accurately stratify patients with DFU at high risk for all-cause mortality, cardiovascular mortality, and MACE. In recent years, the NPAR has gained attention as a novel composite biomarker increasingly linked to various adverse clinical outcomes. NPAR is derived from the ratio of neutrophil percentage to albumin, simultaneously reflecting systemic inflammatory response and nutritional status.8 Several large-scale studies based on the National Health and Nutrition Examination Survey (NHANES) data have demonstrated that elevated NPAR is significantly associated with increased risks of all-cause and cardiovascular mortality in diabetic patients. For instance, a study involving 8560 participants with diabetes and prediabetes demonstrated that individuals in the highest NPAR quartile had a 54% increased risk of all-cause mortality (HR 1.54, 95% CI 1.28–1.87) and a 104% increased risk of cardiovascular mortality (HR 2.04, 95% CI 1.47–2.84).9 Furthermore, elevated NPAR was significantly associated with a higher incidence of diabetic retinopathy (DR) (OR 1.24, 95% CI: 1.04–1.48).10 In other pathological conditions, NPAR has also been correlated with adverse outcomes in sepsis, heart failure, community-acquired pneumonia, and certain malignancies.11–13 However, the prognostic utility of NPAR specifically in individuals with DFU, particularly its association with endpoints such as all-cause mortality, cardiovascular mortality, and MACE, remains unexplored. The present study sought to evaluate the relationship between baseline NPAR and the incidence of these three clinical outcomes in a DFU population through a retrospective cohort analysis. Materials and Methods Data Source This study was a single-center retrospective cohort study utilizing data extracted from the electronic medical record system of Air Force Medical Center. We consecutively enrolled patients hospitalized with DFU between January 2015 and December 2022. The study protocol was approved by the Institutional Review Board of Air Force Medical Center. The inclusion criteria were as follows: Meeting the diagnostic criteria for T2DM;14 Wagner grade 1–5 DFU. The exclusion criteria were as follows: Foot ulcers caused by conditions other than T2DM; Lower extremity ulcers (non-foot) caused by diabetes; Patients with a Wagner grade 0; Patients with missing values for the dependent variable NPAR (Figure 1). Flow chart of the participants in the study. Measurement of NPAR Fasting venous blood samples were collected from all patients on the day following hospital admission. Neutrophil percentage (NEUT%) was defined as the proportion of neutrophils among total white blood cells, expressed as a percentage. NEUT% was measured using a Beckman Coulter AU5800 automated biochemical analyzer with WDF lytic reagent and stain, and calculated automatically by the system. Serum albumin concentration was determined using the bromocresol green method, with results reported in g/dL. The NPAR was calculated using the formula: NEUT% × 100 / ALB (g/dL).15 All laboratory analyses were performed in the central laboratory, which adheres to daily internal quality control procedures. Endpoint This study defined triple endpoints, including all-cause mortality, cardiovascular mortality, and MACE. MACE was defined as a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular mortality.16 Cardiovascular mortality encompassed deaths attributed to coronary heart disease (such as myocardial infarction or ischemic heart disease), cerebrovascular events (eg, stroke), heart failure, peripheral arterial disease, or other cardiovascular causes.17 Patient follow-up was completed in batch in March 2024 using a multimodal verification mechanism incorporating telephone interviews, text messages, electronic medical records, and mortality data from the Center for Disease Control to ascertain endpoint events. The median follow-up duration was 3.6 years. Covariates All covariates were extracted from baseline records upon admission. The same set of covariates was adjusted for in the analyses of all-cause mortality, cardiovascular mortality, and MACE. Demographic indicators: age was determined based on identification card information; sex was categorized as male or female. Lifestyle factors: body mass index (BMI) was calculated from measured height and weight at admission (kg/m²); smoking history was defined as current or previous continuous smoking for ≥6 months. Biochemical indicators: glycated hemoglobin (HbA1c), fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), serum creatinine (SCR), and serum uric acid (SUA). Hematological parameters: hemoglobin (HB), white blood cell count (WBC), red blood cell count (RBC), and platelet count (PLT). Diabetes duration was defined as the number of years from initial diagnosis to admission; diabetic foot ulcer duration was defined as the number of days from ulcer onset to admission. Diabetes complications: diabetic retinopathy (DR), diabetic nephropathy (DN), diabetic peripheral neuropathy (DPN), peripheral artery disease (PAD), hypertension, coronary heart disease (CHD), stroke, and hyperlipidemia (HLD). All complications were assessed at admission. Wagner grade was evaluated by specialists according to foot wound (Grade 1: superficial ulcer; Grade 2: involvement of tendons; Grade 3: bone involvement; Grades 4–5: localized or full-foot gangrene).18 All laboratory test results were based on the results of the first fasting blood tests after admission. Statistical Analysis This study utilized specialized statistical software EmpowerStats (Version 2.0) and IBM SPSS (Windows 27.0) for data analysis. Continuous variables were assessed for normality using the Shapiro–Wilk test: data conforming to a normal distribution were expressed as mean ± standard deviation (Mean ± SD), and intergroup comparisons were performed using one-way analysis of variance or independent samples t-test; non-normally distributed data were expressed as median and interquartile range (IQR), and intergroup comparisons were conducted using the Kruskal–Wallis H-test or the Mann–Whitney U-test. Categorical variables were described using frequencies and percentages [n (%)], and differences between groups were assessed using Pearson’s chi-square test or Fisher’s exact test. Patients were categorized into four groups according to quartile of NPAR values, and baseline characteristics were compared across these quartiles. Multivariable-adjusted Cox proportional hazards models were employed to evaluate the association between NPAR and clinical outcomes. Three sequential models were constructed: Model I unadjusted variables; Model II was adjusted for age and sex; Model III was further adjusted for BMI, smoking history, DR, DN, DPN, PAD, hypertension, CHD, stroke, and HLD. Results are presented as hazard ratios with corresponding 95% confidence intervals. To assess the added value of the composite NPAR index, we used Stata statistical software and employed the comparison method of the nested Cox regression model. Specifically, we constructed two models: one that only included neutrophils percentage, and the other that included our composite index NPAR. We used the likelihood ratio test (likelihood ratio test, LRT) to verify whether the goodness of fit has significantly improved, and simultaneously compared the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) information criteria. The lower the AIC and BIC values, the better the balance between the goodness of fit and complexity achieved by the model, thereby determining the optimal model (Supplementary Table S2). Subgroup analyses and nonlinearity tests were conducted by stratifying according to sex, age (<65 / ≥65 years), BMI (<24 / ≥24 kg/m²), DPN, DR, CHD, and smoking status. The potential nonlinear relationship between NPAR and outcomes was examined using restricted cubic spline (RCS) regression, with the nonlinear effect tested by the log-likelihood ratio test. Kaplan–Meier analysis was performed to plot survival curves illustrating cumulative survival rates across NPAR groups. Event distributions were visualized, and censored events were indicated by vertical tick marks (“I”) to facilitate an intuitive assessment of follow-up completeness. Between-group differences were evaluated using the Log rank test. Mediation analysis was performed to explore the extent to which the association between baseline NPAR and the risks of all-cause mortality, cardiovascular mortality, and MACE was explained by estimated glomerular filtration rate (eGFR). All analyses were two-sided, and a P-value < 0.05 was considered statistically significant. The overall missing rate of covariates is 19.5%. To address the potential bias introduced by missing data, we conducted a sensitivity analysis by excluding the participants with missing data. The results were consistent with the main conclusions obtained using the multiple imputation method (MI), thereby confirming the robustness of our findings (Supplementary Table S1). Multiple imputation maximizes sample size retention, minimizes potential bias, and enables more robust statistical inference. Results Baseline Characteristics of Study Participants This study enrolled a total of 1175 eligible patients with DFU. Table 1 presents the baseline demographic and clinical characteristics of the patients grouped according to NPAR quartiles. Overall, the mean age of the patients was 62.0 ± 11.6 years, and 850 (72.3%) were male. The median NPAR among enrolled patients was 17.8 (interquartile range [IQR] 15.0–21.8). Compared to those in the lowest NPAR quartile (Q1), patients in the highest quartile (Q4) exhibited a more adverse clinical profile. The Q4 group was older and demonstrated poorer glycemic control. Hematological parameters in Q4 group showed elevated WBC, PLT, neutrophil count, and SCR, along with reduced HB, RBC count, and serum albumin. Lipid profiles indicated generally lower levels of LDL, TC, TG, and HDL. Additionally, these patients had lower SUA and BMI. Regarding comorbidities, the Q4 group had a significantly higher prevalence of hypertension, more advanced Wagner grades, and diabetic kidney disease. Table 1Baseline Characteristics of the Study Population Stratified by NPAR QuartilesCharacteristicsTotalQ1 (NPAR≦15.0)Q2 (15.0 0.05) (Figure 2). Nonlinear Association of NPAR with all-cause (A), cardiovascular mortality (B) and MACE Risk (C): Threshold Effect Identified by Segmented Regression. Kaplan-Meier Survival Curve Assessment Kaplan–Meier survival analysis revealed that elevated baseline NPAR was significantly associated with increased risks of all-cause mortality, cardiovascular mortality, and MACE in patients with DFU (Log rank test, all P < 0.001). A dose-dependent increase in the risk of all three outcomes was observed across ascending NPAR quartiles, with the highest risk evident in the Q4 group. Specifically, the risk of cardiovascular mortality in the Q4 group was approximately threefold higher than that in the Q1 group (Figure 3A–C). The censoring event plot (Figure 3D) demonstrated relatively low proportions of censored events across all NPAR groups throughout the follow-up period, indicating satisfactory data completeness and minimal impact on the validity of the survival estimates. (A) Kaplan-Meier curve demonstrating the association between NPAR and all-cause mortality.(B) Kaplan-Meier curve illustrating the relationship between NPAR and cardiovascular disease mortality. (C) Kaplan-Meier curve showing the correlation between NPAR and MACE incidence.NPAR: Neutrophil Percentage-to-Albumin Ratio. (D)The upper chart (Number at risk) lists the number of surviving patients still under observation without experiencing endpoint events in each group (Q1-Q4) at various time points. The lower chart (Number of censoring) displays data censoring events (patients who exited the study without recorded endpoint events) across corresponding time points and groups, with bar height representing the number of censored cases at each time point. Mediation Analysis of NPAR for All-Cause Mortality, Cardiovascular Mortality and MACE in Patients with DFU Model-based mediation analysis indicated a statistically significant indirect pathway via eGFR linking higher NPAR to an increased risk of adverse outcomes (Figure 4). Specifically, for all-cause mortality (Figure 4A), eGFR accounted for 11.7% of the total effect (β = 0.007, P < 0.05). For cardiovascular mortality (Figure 4B), the proportion mediated by eGFR was 7.3%. Regarding MACE risk (Figure 4C), the mediated effect through eGFR was 8.7%. The mediating effect of eGFR on the relationship between NPAR and all-cause mortality (A), cardiovascular mortality (B), and MACE incidence (C); all models were adjusted for age, sex, BMI, smoking status, hypertension, and history of coronary heart disease (CHD).It is important to note that these findings represent statistical associations based on model estimates derived from observational data and do not constitute experimentally verified causal pathways. Discussion This retrospective cohort study demonstrated that elevated baseline NPAR was significantly associated with an increased risk of all-cause mortality, cardiovascular mortality, and MACE. After multivariate adjustment, each unit increase in NPAR was associated with a 5% higher hazard for all-cause mortality and MACE (HR 1.05, 95% CI 1.03–1.07, P < 0.001) and a 6% higher hazard for cardiovascular mortality (HR 1.06, 95% CI 1.04–1.08, P < 0.001). Patients in the highest NPAR quartile (Q4, NPAR ≥21.8) exhibited an 85% significantly increased risk of all-cause mortality compared to those in the lowest quartile (Q1, NPAR ≤15.0) (HR = 1.85, 95% CI: 1.34–2.55, P < 0.001). Similarly elevated risks were observed for cardiovascular mortality (HR = 2.26, 95% CI: 1.53–3.33) and MACE (HR = 2.05, 95% CI: 1.48–2.84). Nonlinear threshold effects were identified between NPAR and all outcomes: below inflection points, risks increased markedly—20.2 for all-cause mortality (P < 0.001), 19.9 for cardiovascular mortality (P < 0.001), and 23.3 for MACE (P < 0.001). Additionally, the indirect effect througheGFR explained 11.7% of the total association of NPAR with all-cause mortality, 7.3% with cardiovascular mortality, and 8.7% with MACE. The findings of this study are consistent with previously reported associations between elevated NPAR and risks of other diseases, such as metabolic syndrome,19 chronic heart failure,20 diabetes,21 diabetic retinopathy10 and diabetic kidney disease.22 A study by Li et al23 retrospectively analyzed 6962 diabetic patients from the NHANES database and demonstrated that each unit increase in NPAR was associated with a 14% and 12% elevation in the risks of all-cause mortality and cardiovascular mortality, respectively. He et al10 evaluated the association between NPAR and diabetic retinopathy risk among 5850 diabetic patients. After multivariate Cox regression adjustment for confounding factors, results indicated that a higher NPAR was an independent risk factor for DR compared to lower NPAR levels (OR: 1.18, 95% CI: 1.00–1.39; OR: 1.24, 95% CI: 1.04–1.48). Furthermore, a study by Li et al22 involving 2263 subjects found that, after adjusting for confounders, the odds ratios for diabetic kidney disease in the second, third, and fourth NPAR quartiles were 1.44 (95% CI: 1.08–1.90), 1.75 (95% CI: 1.33–2.31), and 2.95 (95% CI: 2.22–3.93), respectively, compared to the first quartile, confirming a positive correlation between NPAR and DKD occurrence. To our knowledge, this study is the first to demonstrate a nonlinear association, characterized by a threshold effect, between NPAR and the risks of all-cause mortality, cardiovascular mortality, and MACE in a population with DFU. Additionally, our findings confirm that reduced eGFR plays a critical mediating role in the increased mortality and MACE risks associated with elevated NPAR. These results highlight the importance for clinicians to address systemic inflammation, nutritional status, and renal function in the comprehensive management of DFU to mitigate adverse outcomes. Although the precise biological mechanisms linking NPAR and renal function decline have not been fully elucidated, several plausible pathways have been proposed. Elevated NPAR reflects a state of systemic inflammation and malnutrition. This inflammatory milieu may directly contribute to an intrarenal pro-inflammatory environment, activating resident immune cells and promoting the release of inflammatory cytokines—such as interleukin-6 and tumor necrosis factor-alpha—as well as reactive oxygen species. These processes can induce glomerular endothelial injury, mesangial matrix expansion, and tubulointerstitial fibrosis.24,25 In turn, renal tubulointerstitial fibrosis may further stimulate the release of pro-inflammatory factors and suppress erythropoietin synthesis, leading to aggravated anemia and increased cardiac workload. This establishes a vicious cycle of mutual deterioration of cardiac and renal function, often described as the inflammation–anemia–cardiorenal syndrome.26,27 These pathological changes collectively contribute to the progressive decline in eGFR. The reduction in eGFR may amplify mortality risk through two primary pathways: First, a significant decrease in eGFR implies impaired renal excretory function, leading to the accumulation of uremic toxins. These toxins exhibit multiple cardiovascular toxicities: (1) Endothelial cytotoxicity: impairing vascular endothelial function and promoting atherosclerosis; (2) Pro-fibrotic effects: inducing myocardial fibrosis and vascular calcification; (3) Disruption of autonomic nervous regulation: increasing the risk of malignant arrhythmias. These effects directly contribute to the occurrence of cardiovascular events and increased mortality risk.28,29 Second, eGFR decline activates the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS). The chronic overactivation of RAAS and SNS results in water and sodium retention, volume overload, vasoconstriction, and elevated blood pressure, exacerbating heart failure and myocardial remodeling, ultimately leading to worse clinical outcomes.30 These mechanisms also to some extent explain why NPAR performs better in DFU. This might be related to the inflammatory state and nutrient consumption in DFU. However, this study has several limitations. First, as a single-center retrospective cohort analysis, it may be subject to selection bias and influenced by regional variations in clinical practice; future prospective studies are warranted for further validation. Second, NPAR was measured only once at baseline, which does not capture its dynamic changes over time and their potential impact on outcomes. Additionally, unmeasured confounding factors may have influenced the observed associations. Therefore, the observed associations, including the mediation effects involving eGFR, should be interpreted as statistical correlations rather than evidence of a causal pathway. Further studies are needed to validate these mechanistic links. Conclusion In summary, in this retrospective cohort, an elevated baseline level of NPAR was independently associated withincreased long-term risks of all-cause mortality, cardiovascular mortality, and MACE in patients with DFU. This association is partly related to impaired kidney function. Owing to its derivation from routine blood tests and its advantages in simplicity, cost-effectiveness, utility and superiority over single indicators (such as the percentage of neutrophils), NPAR is a valuable tool for identifying high-risk patients regarding mortality and MACE. This makes it highly suitable for clinical risk assessment. Acknowledgments The authors gratefully acknowledge the multifaceted support received during the completion of this study. We extend our sincere gratitude to Professors Da Zhang for her invaluable guidance in the design of the research and the preparation of the paper. We also thank our colleagues, including Lulu Liu and others, for their assistance in experimental work and data analysis. I am also very thankful to the reviewers for their rigorous evaluation and helpful comments regarding the incremental predictive value of the NPAR index. Funding Statement This study was supported by a grant from the Clinical Trial Project of Air Force Medical Center (2 021LC018). Data Sharing Statement The datasets analyzed during the current study are not publicly available due to patient privacy but are available from the corresponding author upon reasonable request. Ethics Approval and Consent to Participate This study was conducted in accordance with the Declaration of Helsinki and reported in adherence to the REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) guidelines. As a retrospective analysis, this study was granted an exemption from patient informed consent. The data collection protocol was approved by the Institutional Review Board of Air Force Medical Center (Approval No. AFMC-2024-64-PJ01). Author Contributions Maolin Tian: Conceptualization, Investigation, Methodology, Software, Visualization, Writing–original draft. Lulu Liu: Data Curation, Resources, Writing–review & editing. Yukun Tao: Formal Analysis, Investigation, Validation, Writing–review & editing. Jinzheng Hou: Investigation, Resources, Writing–review & editing. Guangxin Zhou: Formal Analysis, Visualization, Writing–review & editing. Li Xiao: Data Curation, Validation, Writing–review & editing. Huijuan Zhu: Validation, Resources, Writing–review & editing. Di Zhu: Project Administration, Methodology, Writing–review & editing. Da Zhang: Conceptualisation; Project Administration; Supervision; Writing–review & editing. All authors gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors have nothing to declare for this study. References Associated Data Data Availability Statement The datasets analyzed during the current study are not publicly available due to patient privacy but are available from the corresponding author upon reasonable request.